Lewes, DE -- (SBWire) -- 08/06/2013 --LeadingStockAlerts is a financial marketing firm that specializes in assisting the underserved small cap and micro-cap stock community. Our Today’s Focus is on: Rentech, Inc. (NYSEMKT:RTK), Mast Therapeutics Inc (NYSEMKT:MSTX), North American Palladium Ltd (USA) (NYSEMKT:PAL), Hemispherx BioPharma, Inc (NYSEMKT:HEB)

Rentech, Inc. (NYSEMKT:RTK) gained volume of 2.03 million shares and the average volume of the stock remained 2.23 million shares. The 52 week range of the stock remained $1.82 - $3.18 and the day range was $2.00 - $2.09.The stock opened the session at $2.09, remained amid the day range of $2.00 - $2.09, and closed the session at $2.03. The stock showed a negative performance of -3.79% in previous trading session. Rentech, Inc., through its subsidiaries, engages in the manufacture and sale of natural-gas based nitrogen fertilizer products in the United States and Brazil. Its products include ammonium sulfate, sulfuric acid, and ammonium thiosulfate used in the production of corn, soybeans, potatoes, cotton, canola, alfalfa, and wheat.

Has RTK Found The Bottom and Ready To Move Up? Find Out Here

In previous session, Mast Therapeutics Inc (NYSEMKT:MSTX) traded 1.87 million shares and the average volume of the stock remained 1.54 shares. The 52 week range of the stock remained $0.41 - $0.87. The stock was a bear and dropped -2.63%, while its closing price stayed at $0.440. The market capitalization of the stock remained 42.36 million. The half-yearly trend of the stock remained negative -43.38%. Mast Therapeutics, Inc., a biopharmaceutical company, focuses on developing therapies for serious or life-threatening diseases. Its lead product candidate includes MST-188, a product candidate that has hemorheologic, cytoprotective, and anti-inflammatory properties, which is in phase 3 study for the treatment of sickle cell disease in patients.

Has MSTX Found The Bottom And Ready To Gain Momentum? Find Out Here

North American Palladium Ltd (USA) (NYSEMKT:PAL)volume of the stock was 1.83 million shares in the most recent session and the average volume remained 1.32 million shares. The stock boosted +2.52% and finished the prior session at the closing price of $1.22. The stock traded 1.84 million shares in its previous trading session and its average volume remained 1.32 million shares. North American Palladium Ltd. produces precious metals in Canada. It explores for palladium, platinum, nickel, gold, copper, and other metals.

Will PAL Continue To Move Higher? Find Out Here

Hemispherx BioPharma, Inc (NYSEMKT:HEB) traded with volume of 1.75 million shares and the average volume of the stock remained 470,329 shares. The stock grew +6.56% and finished the trading at $0.260. The market capitalization of the stock remained 43.48 million. The beta of the stock remained 1.36. Hemispherx Biopharma, Inc., a specialty pharmaceutical company, engages in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders.

Why Should Investors Buy HEB After The Recent Gain? Just Go Here and Find Out

About LeadingStockAlerts:
LeadingStockAlerts is a financial marketing firm that specializes in assisting the underserved small cap and micro-cap stock community.

Our site has been the clear choice for today’s investors and day-traders. As one of the internet’s premiere financial destinations, we offer the investment community some of the market’s leading emerging opportunities. Using a balanced combination of industry experience and high-tech offerings, this site keeps you ahead of the curve and ahead of the bell.

Disclaimer:
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT OR WEBSITE. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice.

The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice. The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.

Read Full Disclaimer at: http://leadingstockalerts.com/disclaimer/